C atheter ablation of atrial fibrillation (AF) has undergone considerable development within the last 15 years. Originally, the procedure was predominantly reserved for relatively young patients with no significant structural heart disease. Subsequently, more elderly patients and patients with significant structural heart disease and better glycemic control and lipid profiles. Reviews were every 3 months for the first year and then every 6 months thereafter, including ambulatory 7-day monitoring at each review.
C atheter ablation of atrial fibrillation (AF)
has undergone considerable development within the last 15 years. Originally, the procedure was predominantly reserved for relatively young patients with no significant structural heart disease. Subsequently, more elderly patients and patients with significant structural heart disease and substantial numbers of cardiac risk factors have been treated with catheter ablation. For example, within the last 10 years, the mean age of patients undergoing AF ablation in our laboratory increased from 54 to 67 years. Recommendations for patient selection, procedural techniques, patient management, and follow-up were recently updated in the expert consensus statement (1) .
In addition to further reductions in the complication rate, another major target for improving this relatively invasive catheter procedure is reduction of the necessity for redoing procedures. In the young and otherwise healthy patient population undergoing AF ablation, the typical reason for arrhythmia recurrences (although not always) is reconnection of the initially isolated pulmonary veins. With inclusion of patients who have significant structural heart disease and substantial numbers of cardiac risk factors, this scenario is more complex and combined with our still-limited understanding of AF pathophysiology.
Besides the well-accepted role of pulmonary vein foci in triggering the arrhythmia, the nature of the substrate maintaining AF is still under debate and was recently called the "unknown species" in an editorial (2) . Within the last decade, data on the relationship between AF and obesity, obstructive sleep apnea (OSA), alcohol consumption, and cardiometabolic risk factors have emerged (3) (4) (5) (6) . Furthermore, in a recently published randomized clinical study (7), weight reduction plus intensive general risk factor management (RFM) resulted in reduced AF symptom burden and severity. AF also has a genetic component, and a primary fibrotic atrial cardiomyopathy was described as a specific disease supplying substrates for AF, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications (8, 9) . Certainly the "unknown species" human AF substrate as well as the specific roles of promoters/ modulators of AF pathophysiology (e.g., cardiac risk factors, inflammation, surgery, cancer) deserve further evaluation.
